iShares Biotechnology ETF

IBB

Market cap $9.21B

First Trust NYSE Arca Biotechnology Index Fund offers a more concentrated portfolio with only 30 holdings compared to the 248 positions in iShares Biotechnology ETF iShares Biotechnology ETF is the larger and more established fund, having launched in 2001 and managing $9.6 billion in assets under management First Trust NYSE Arca Biotechnology Index Fund has achieved a higher total return over both one-year and five-year horizons

The iShares U.S. Pharmaceuticals ETF (IHE) offers a lower expense ratio and a significantly higher dividend yield than the iShares Biotechnology ETF (IBB). IBB offers broader diversification, with 248 holdings compared to just 56 for IHE.

Western biotechs get a new playbook with tighter controls to stay ahead of China's “fast follower” pharmaceutical pipeline.

Healthcare stocks are attractive in a choppy market. These funds, focusing on the broader sector, drugmakers, and biotechs, are worth a look.

Janus Henderson portfolio manager Dan Lyons discusses why he sees opportunities for market outperformance in the healthcare sector as innovations in biotechnology, pharmaceuticals and medical devices proliferate. Check out our daily newsletter!

State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio of 0.08% compared to 0.44% for iShares Biotechnology ETF. iShares' ETF provides concentrated exposure to 248 biotechnology stocks while the SPDR fund holds 59 diverse healthcare names.

Jared Holz, Mizuho, joins 'Power Lunch' to discuss the recent performance in the healthcare sector, why sentiment has turned and much more.

Big pharma's patent cliff risk is somewhat overstated, as layered IP and litigation often extend exclusivity beyond headline expiries. Incremental innovation—new formulations, improved delivery, and higher dosing—effectively extends product lifecycles and drives shareholder value.

LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.

A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market.